活性药物成分CDMO市场－全球产业规模、份额、趋势、机会和预测，按分子类型、合成方法、药物类型、工作流程、应用、地区和竞争格局划分，2020-2030年预测

2024年全球活性药物成分（API）合约开发与生产组织（CDMO）市场规模为9,698万美元，预计至2030年将以6.1%的复合年增长率成长至1.3835亿美元。活性药物成分（API）合约开发与生产组织（CDMO）以合约形式为製药公司提供全面的API开发和生产服务，协助其进行药物合成、製程优化、规模化生产和法规遵循。市场成长的主要驱动因素包括：不断增加的药物研发投入、全球慢性病盛行率的上升（需要新的疗法）以及药物分子日益复杂化。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球活性药物成分CDMO市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依分子类型（小分子、大分子）分类
  • 透过合成（生物技术、合成）
  • 依药物类型（创新药、仿製药）
  • 按工作流程（临床、商业）
  • 依专业方向（心臟科、肿瘤学、眼科学、神经病学、骨科学、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美活性药物成分CDMO市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲活性药物成分CDMO市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区活性药物成分CDMO市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲活性药物成分CDMO市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美活性药物成分CDMO市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球活性药物成分CDMO市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Cambrex Corporation
• Thermo Fisher Scientific, Inc.
• Recipharm AB
• Corden Pharma International GmbH
• Samsung Biologics Co., Ltd.
• Lonza Group Ltd.
• Siegfried Holding AG
• Piramal Pharma Limited
• AbbVie Inc.
• Catalent, Inc.

第十六章：策略建议

第17章调查会社について・免责事项

The Global Active Pharmaceutical Ingredients CDMO Market, valued at USD 96.98 Million in 2024, is projected to experience a CAGR of 6.1% to reach USD 138.35 Million by 2030. An Active Pharmaceutical Ingredient (API) Contract Development and Manufacturing Organization (CDMO) provides comprehensive development and manufacturing services for APIs on a contract basis, assisting pharmaceutical firms with drug substance synthesis, process optimization, scalable production, and regulatory compliance. The market's growth is primarily driven by increasing pharmaceutical research and development investments, the escalating global prevalence of chronic diseases necessitating new therapies, and the growing complexity of drug molecules.

Key Market Drivers

The robust pharmaceutical research and development pipeline, along with consistent new drug approvals, significantly drives the Global Active Pharmaceutical Ingredients CDMO Market. Substantial industry investment in novel therapies necessitates specialized API development and manufacturing expertise. According to the International Federation of Pharmaceutical Manufacturers & Associations, global pharmaceutical R&D expenditure reached USD 204 billion in 2023, underscoring this commitment to innovation and growth. This sustained investment fuels demand for CDMOs capable of supporting complex early-stage development through commercial scale production. The global API manufacturing landscape features geographically diversified capabilities, crucial for supply chain resilience. For instance, according to the Pacific Forum, in 2022, India housed 18% of global API manufacturing facilities, demonstrating the importance of specialized centers in meeting worldwide demand.

Key Market Challenges

A significant challenge impeding the growth of the Global Active Pharmaceutical Ingredients CDMO Market involves maintaining adequate transparency and control over outsourced production processes. This difficulty can lead to struggles in pinpointing the origin of manufacturing issues, navigating complex supply chains, and potentially causing a loss of critical knowledge for the contracting pharmaceutical company. Without clear visibility and stringent control, pharmaceutical firms face heightened risks regarding product quality and regulatory compliance.

Key Market Trends

The rising outsourcing of biologics and advanced therapies production represents a pivotal trend in the Global Active Pharmaceutical Ingredients CDMO Market. As pharmaceutical companies increasingly focus on complex biopharmaceuticals, including monoclonal antibodies, cell, and gene therapies, the specialized expertise and infrastructure required for their development and manufacturing often necessitate external partnerships. These advanced modalities demand sophisticated facilities, stringent quality control, and specialized technical personnel that many pharmaceutical companies prefer to outsource to dedicated CDMOs. The U. S. Food and Drug Administration (FDA) reported that in 2023, the Center for Biologics Evaluation and Research (CBER) approved 22 new Biologics License Applications (BLAs), nearly doubling the approvals from 2021 and 2022, underscoring the expanding pipeline in this segment.

Key Market Players

• Cambrex Corporation
• Thermo Fisher Scientific, Inc.
• Recipharm AB
• Corden Pharma International GmbH
• Samsung Biologics Co., Ltd.
• Lonza Group Ltd.
• Siegfried Holding AG
• Piramal Pharma Limited
• AbbVie Inc.
• Catalent, Inc.

Report Scope:

In this report, the Global Active Pharmaceutical Ingredients CDMO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Active Pharmaceutical Ingredients CDMO Market, By Molecule Type:

• Small Molecule
• Large Molecule

Active Pharmaceutical Ingredients CDMO Market, By Synthesis:

• Biotech
• Synthetic

Active Pharmaceutical Ingredients CDMO Market, By Drug Type:

• Innovative
• Generics

Active Pharmaceutical Ingredients CDMO Market, By Workflow:

• Clinical
• Commercial

Active Pharmaceutical Ingredients CDMO Market, By Application:

• Cardiology
• Oncology
• Ophthalmology
• Neurology
• Orthopedic
• Other

Active Pharmaceutical Ingredients CDMO Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Active Pharmaceutical Ingredients CDMO Market.

Available Customizations:

Global Active Pharmaceutical Ingredients CDMO Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Active Pharmaceutical Ingredients CDMO Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Molecule Type (Small Molecule, Large Molecule)
  • 5.2.2. By Synthesis (Biotech, Synthetic)
  • 5.2.3. By Drug Type (Innovative, Generics)
  • 5.2.4. By Workflow (Clinical, Commercial)
  • 5.2.5. By Application (Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other)
  • 5.2.6. By Region
  • 5.2.7. By Company (2024)
• 5.3. Market Map

6. North America Active Pharmaceutical Ingredients CDMO Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Molecule Type
  • 6.2.2. By Synthesis
  • 6.2.3. By Drug Type
  • 6.2.4. By Workflow
  • 6.2.5. By Application
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Active Pharmaceutical Ingredients CDMO Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Molecule Type
      • 6.3.1.2.2. By Synthesis
      • 6.3.1.2.3. By Drug Type
      • 6.3.1.2.4. By Workflow
      • 6.3.1.2.5. By Application
  • 6.3.2. Canada Active Pharmaceutical Ingredients CDMO Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Molecule Type
      • 6.3.2.2.2. By Synthesis
      • 6.3.2.2.3. By Drug Type
      • 6.3.2.2.4. By Workflow
      • 6.3.2.2.5. By Application
  • 6.3.3. Mexico Active Pharmaceutical Ingredients CDMO Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Molecule Type
      • 6.3.3.2.2. By Synthesis
      • 6.3.3.2.3. By Drug Type
      • 6.3.3.2.4. By Workflow
      • 6.3.3.2.5. By Application

7. Europe Active Pharmaceutical Ingredients CDMO Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Molecule Type
  • 7.2.2. By Synthesis
  • 7.2.3. By Drug Type
  • 7.2.4. By Workflow
  • 7.2.5. By Application
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Active Pharmaceutical Ingredients CDMO Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Molecule Type
      • 7.3.1.2.2. By Synthesis
      • 7.3.1.2.3. By Drug Type
      • 7.3.1.2.4. By Workflow
      • 7.3.1.2.5. By Application
  • 7.3.2. France Active Pharmaceutical Ingredients CDMO Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Molecule Type
      • 7.3.2.2.2. By Synthesis
      • 7.3.2.2.3. By Drug Type
      • 7.3.2.2.4. By Workflow
      • 7.3.2.2.5. By Application
  • 7.3.3. United Kingdom Active Pharmaceutical Ingredients CDMO Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Molecule Type
      • 7.3.3.2.2. By Synthesis
      • 7.3.3.2.3. By Drug Type
      • 7.3.3.2.4. By Workflow
      • 7.3.3.2.5. By Application
  • 7.3.4. Italy Active Pharmaceutical Ingredients CDMO Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Molecule Type
      • 7.3.4.2.2. By Synthesis
      • 7.3.4.2.3. By Drug Type
      • 7.3.4.2.4. By Workflow
      • 7.3.4.2.5. By Application
  • 7.3.5. Spain Active Pharmaceutical Ingredients CDMO Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Molecule Type
      • 7.3.5.2.2. By Synthesis
      • 7.3.5.2.3. By Drug Type
      • 7.3.5.2.4. By Workflow
      • 7.3.5.2.5. By Application

8. Asia Pacific Active Pharmaceutical Ingredients CDMO Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Molecule Type
  • 8.2.2. By Synthesis
  • 8.2.3. By Drug Type
  • 8.2.4. By Workflow
  • 8.2.5. By Application
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Active Pharmaceutical Ingredients CDMO Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Molecule Type
      • 8.3.1.2.2. By Synthesis
      • 8.3.1.2.3. By Drug Type
      • 8.3.1.2.4. By Workflow
      • 8.3.1.2.5. By Application
  • 8.3.2. India Active Pharmaceutical Ingredients CDMO Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Molecule Type
      • 8.3.2.2.2. By Synthesis
      • 8.3.2.2.3. By Drug Type
      • 8.3.2.2.4. By Workflow
      • 8.3.2.2.5. By Application
  • 8.3.3. Japan Active Pharmaceutical Ingredients CDMO Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Molecule Type
      • 8.3.3.2.2. By Synthesis
      • 8.3.3.2.3. By Drug Type
      • 8.3.3.2.4. By Workflow
      • 8.3.3.2.5. By Application
  • 8.3.4. South Korea Active Pharmaceutical Ingredients CDMO Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Molecule Type
      • 8.3.4.2.2. By Synthesis
      • 8.3.4.2.3. By Drug Type
      • 8.3.4.2.4. By Workflow
      • 8.3.4.2.5. By Application
  • 8.3.5. Australia Active Pharmaceutical Ingredients CDMO Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Molecule Type
      • 8.3.5.2.2. By Synthesis
      • 8.3.5.2.3. By Drug Type
      • 8.3.5.2.4. By Workflow
      • 8.3.5.2.5. By Application

9. Middle East & Africa Active Pharmaceutical Ingredients CDMO Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Molecule Type
  • 9.2.2. By Synthesis
  • 9.2.3. By Drug Type
  • 9.2.4. By Workflow
  • 9.2.5. By Application
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Active Pharmaceutical Ingredients CDMO Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Molecule Type
      • 9.3.1.2.2. By Synthesis
      • 9.3.1.2.3. By Drug Type
      • 9.3.1.2.4. By Workflow
      • 9.3.1.2.5. By Application
  • 9.3.2. UAE Active Pharmaceutical Ingredients CDMO Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Molecule Type
      • 9.3.2.2.2. By Synthesis
      • 9.3.2.2.3. By Drug Type
      • 9.3.2.2.4. By Workflow
      • 9.3.2.2.5. By Application
  • 9.3.3. South Africa Active Pharmaceutical Ingredients CDMO Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Molecule Type
      • 9.3.3.2.2. By Synthesis
      • 9.3.3.2.3. By Drug Type
      • 9.3.3.2.4. By Workflow
      • 9.3.3.2.5. By Application

10. South America Active Pharmaceutical Ingredients CDMO Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Molecule Type
  • 10.2.2. By Synthesis
  • 10.2.3. By Drug Type
  • 10.2.4. By Workflow
  • 10.2.5. By Application
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Active Pharmaceutical Ingredients CDMO Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Molecule Type
      • 10.3.1.2.2. By Synthesis
      • 10.3.1.2.3. By Drug Type
      • 10.3.1.2.4. By Workflow
      • 10.3.1.2.5. By Application
  • 10.3.2. Colombia Active Pharmaceutical Ingredients CDMO Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Molecule Type
      • 10.3.2.2.2. By Synthesis
      • 10.3.2.2.3. By Drug Type
      • 10.3.2.2.4. By Workflow
      • 10.3.2.2.5. By Application
  • 10.3.3. Argentina Active Pharmaceutical Ingredients CDMO Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Molecule Type
      • 10.3.3.2.2. By Synthesis
      • 10.3.3.2.3. By Drug Type
      • 10.3.3.2.4. By Workflow
      • 10.3.3.2.5. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Active Pharmaceutical Ingredients CDMO Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Cambrex Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Thermo Fisher Scientific, Inc.
• 15.3. Recipharm AB
• 15.4. Corden Pharma International GmbH
• 15.5. Samsung Biologics Co., Ltd.
• 15.6. Lonza Group Ltd.
• 15.7. Siegfried Holding AG
• 15.8. Piramal Pharma Limited
• 15.9. AbbVie Inc.
• 15.10. Catalent, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer